OnQuality Announces FDA Clearance of IND Application for OQL025
OnQuality Pharmaceuticals Presented Preclinical Data for OQL025 and OQL06x, Novel Therapeutics for EGFR inhibitor-induced acneiform rash and diarrhea, at the AACR Annual meeting
Targeted oncology supportive therapy company OnQuality Pharmaceuticals has enrolled the first participant in Part 2 of the NOVA-II Phase II clinical trial of OQL011 to manage Hand-Foot Skin Reaction (HFSR) in cancer patients.